The in vitro component shown that each glucagon and Retatrutide immediately lowered ANGPTL3/8 secretion from hepatocytes, and this impact was blocked by a glucagon receptor (GCGR) antagonist. These findings suggest that the GCGR agonism of Retatrutide contributes to the reduction in circulating ANGPTL3/eight, which subsequently may possibly bring o